Radiopharmaceuticals for Imaging Brain Synuclein

用于脑突触核蛋白成像的放射性药物

• 批准号: 6992531
• 负责人: DANIEL M SKOVRONSKY
• 金额: $ 10万
• 依托单位: AVID RADIOPHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-01 至 2006-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6992531
• 关键词: Lewy body; alpha synuclein; autoradiography; bioimaging /biomedical imaging; biomarker; biotechnology; brain disorder diagnosis; brain imaging /visualization /scanning; dementia; diagnosis design /evaluation; diagnosis quality /standard; human tissue; molecular probes; neuropathology; positron emission tomography; postmortem; protein binding; radiopharmacology; recombinant proteins; single photon emission computed tomography; technology /technique development

DESCRIPTION (provided by applicant): The long-term goal of this project is the development of radiopharmaceuticals for diagnosis of Dementia with Lewy Bodies (DLB). DLB is the second most common cause of dementia in the United States; although the disease requires specific pharmacologic management, current diagnostic methods are extremely inaccurate. DLB is often misdiagnosed as Alzheimer's disease or Parkinson's disease with dementia. This project is driven by the hypothesis that in vivo detection of synuclein pathology by positron emission computed tomography imaging (using radiolabeled synuclein binding probes) would allow for the early and definitive diagnosis of DLB, thus improving treatment of these patients. Phase I of this project will assess the feasibility of this approach through the synthesis and in vitro evaluation of potential synuclein probes. Specific aims of Phase I include: 1) Synthesis of proposed probes; 2) Testing the probes ability to label brain synuclein pathology; and 3) Measuring the affinity of the probes for synuclein pathology. If suitable probes are identified, Phase II will optimize the structure and test biodistribution and efficacy of the probes in transgenic mice. Probes with appropriate properties will be selected for clinical development to yield an innovative product for the evaluation and diagnosis of DLB.

描述（由申请人提供）： 该项目的长期目标是开发用于用路易体（DLB）诊断痴呆症的放射性药物（DLB）。 DLB是美国第二常见的痴呆症原因。尽管该疾病需要特定的药理管理，但当前的诊断方法极为不准确。 DLB通常被误诊为患有痴呆症的阿尔茨海默氏病或​​帕金森氏病。该项目是由以下假设驱动的：通过正电子发射计算机断层扫描成像（使用放射性标记的突触核蛋白结合探针）在体内检测突触核蛋白病理学，将允许对DLB的早期和确定的诊断，从而改善对这些患者的治疗。 该项目的第一阶段将通过对潜在突触核蛋白探针的合成和体外评估来评估这种方法的可行性。第一阶段的具体目的包括：1）提议的探针的合成； 2）测试探针标记脑核蛋白病理学的能力； 3）测量探针对突触核蛋白病理学的亲和力。如果确定了合适的探针，II期将优化转基因小鼠探针的生物分布和疗效。将选择具有适当特性的探针进行临床开发，以产生用于评估和诊断DLB的创新产品。